Company / Operating Cash Flow
Anixa Biosciences Inc Operating Cash Flow History
FY2014-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$7.3M
FY2024
5-year range
-$7.3M / -$4.3M
FY2020-FY2024
Trend
-13.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has declined for 7 consecutive years, from $1M in FY2016 to -$7M in FY2024.
Based on SEC 10-K filings.
-$7M in FY2024.
Declined from -$5M to -$7M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Anixa Biosciences Inc's operating cash flow has declined for 7 consecutive years.
- In FY2024, operating cash flow decreased 13.0% year-over-year.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.53 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$7.3M | -13.0% |
| FY2023 | -$6.5M | -31.5% |
| FY2022 | -$4.9M | -4.1% |
| FY2020 | -$4.7M | -11.0% |
| FY2019 | -$4.3M | -12.6% |
| FY2018 | -$3.8M | -12.3% |
| FY2017 | -$3.4M | -348.0% |
| FY2016 | $1.4M | +157.3% |
| FY2015 | -$2.4M | +25.3% |
| FY2014 | -$3.2M | -345.1% |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026